IFF Trims Business Focus While SuanNutra Adds Scale In Supplement Ingredients Portfolio Deal
Deal expected to close during 2026 includes IFF’s portfolio of botanical extracts, vitamins and minerals and food enhancement activities, including its natural colors and antioxidants and some flavor activities in Peru. Financial terms weren’t disclosed.
HBW Insight - July 20, 2026

‘World’s Best-Smelling Sunscreen’ Claim Puffery Until Paired With Reviews – NAD
The National Advertising Division reviewed a challenge brought by Nivea marketer Beiersdorf against Vacation for ‘World’s Best-Smelling Sunscreen’ claim.
HBW Insight - July 20, 2026

Deal Watch: Ligand Closes XOMA Royalty Buyout, Won’t Chase Larger Royalty Players
Ligand wants to focus on small, single-asset deals, rather than try to match Blackstone, Royalty Pharma for size. Plus deals involving Summit/Biossil, Matinas/Azurity, Chemomab/Scipher and more.
Scrip - July 20, 2026

BMS Boosts AI Capabilities With NVIDIA Collaboration Expansion
The drugmaker is building what it called a “factory” powered by AI based on supercomputers from NVIDIA for drug discovery and development.
Scrip - July 20, 2026

French SMEs Blame Failure To Scale On EU MDR And Reimbursement Models
A new white paper from industry association Snitem and the Sapiens Institute focuses on finance failings and proposes ideas to support French SMEs and start-ups and spur medtech innovation to develop French medtech industry leaders. Sensome president Franz Bozsak adds his perspective.
Medtech Insight - July 20, 2026

Alzheimer’s AAIC Video Interview: Denali CEO On Breaking Through To The Brain
CEO Ryan Watts talks about Denali's recently approved Hunter syndrome drug Avlayah, which uses its brain-penetrant TransportVehicle technology that is also being used in candidates for Alzheimer's and other neurological conditions.
Scrip - July 20, 2026

The Generics Bulletin Podcast: Summer Conferences
Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.
Generics Bulletin - July 20, 2026

Only Two Generic Drug Makers At Administration’s Essential Medicine Production Meeting
The Trump Administration is developing incentives to reshore essential medicine production amid concerns China could disrupt US access to critical drugs and ingredients.
Generics Bulletin - July 20, 2026

Alzheimer’s AAIC Video Interview: Roche Sees Further Potential For Brain Shuttle Technology
Roche's head of neuroscience development Geoff Kerchner discussed latest data from its brain shuttle antibody asset trontinemab, its new Alzheimer's prevention Phase III study, and the technology's potential with other cargoes.
Scrip - July 20, 2026

EU Regulators Flag Probiotics And Ginseng Supplements As Possible ‘Emerging Risks’
Six food supplement ingredients, including ginseng and the probiotic bifidobacterium, have been flagged as possible emerging risks by EU regulators, raising the prospect of future sales restrictions across the bloc.
HBW Insight - July 20, 2026

Claims Open To Dip In The $533m Settlement Pot From US Price-Fixing Saga
Settlements from Apotex, Heritage, Sandoz, Sun Pharma, and Taro have been approved by a US federal court, releasing $533m to end-payers affected by an alleged decade-long generic drug price-fixing conspiracy.
Generics Bulletin - July 20, 2026

Pipeline Watch: Seven Approvals And Nine Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - July 20, 2026

Caremark Settles FTC Case With Sweeping Drug-Pricing Reforms
CVS Caremark will overhaul rebates, patient cost-sharing, spread pricing and pharmacy reimbursement under an FTC settlement projected to deliver billions in savings.
Generics Bulletin - July 20, 2026

No-Regrets Move: PwC Makes The Case For Building Consumer Health Innovation Around Wellness Goals
Consumers are managing their health continuously and across more product categories than ever. PwC's Anthony Bruce says this presents an opportunity for consumer health firms to orientate innovation around the goals, such as sleep, immunity and healthy aging, that consumers are already focused on.
HBW Insight - July 20, 2026

Hidden Cost Of Cancer Drug Shortages: Billions At Risk If Trial Protocols Unravel
Active US drug shortages rose for a third consecutive quarter, risking more clinical trial disruptions. In Vivo examines the likely fallout and explores solutions for cancer drug shortages as ASCO's chief medical officer warns of new drugs facing a potential threat of delays in approvals.
In Vivo - July 20, 2026

UK Lauds Landmark Quarter For Biotech But Public Cash Drought Persists
The BIA says that while the UK's private investors "remain the powerhouse of European fundraising," the public markets are lagging behind the continent's peers, never mind the US.
Scrip - July 20, 2026

HS Market Snapshot: A Heterogeneous Disease Still Waiting For Its Breakthrough
After a decade with just one biologic, hidradenitis suppurativa finally has a crowded pipeline, but doctors still can't reliably predict who any of these drugs will help.
Scrip - July 20, 2026

PolyPeptide Buy To Give Samsung Biologics Capacity In Surging Peptides Sector
Swiss firm's peptide expertise and sites to strengthen Korean giant's global multi-modality manufacturing capabilities.
Scrip - July 20, 2026

Supplement Industry Plants Longtime Use Flag As US Looks At Expanding Peptide Bulk Drugs List
FDA Pharmacy Compounding Advisory Committee on July 23-24 will review numerous peptides for addition to its bulk list for compounding by state-licensed physicians and pharmacists under FD&C Act Section 503A.
HBW Insight - July 20, 2026